Nicoletta Colombo, MD, European Institute of Oncology, Milan, Italy, discusses the results of subgroup analyses from the Phase III KEYNOTE-775 study (NCT03517449) comparing pembrolizumab plus lenvatinib versus treatment of physician’s choice in patients with advanced endometrial cancer. Combination therapy provided a progression-free survival (PFS) benefit compared with treatment of physician’s choice across all different subgroups, including histology, prior lines of therapy, and mismatch repair status. However, although the overall survival (OS) was improved across all histologies, it was less significant for patients that were treated with more than one prior line of platinum-based therapy. This supports the earlier use of pembrolizumab plus lenvatinib in this patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
